Brokerages Set COMPASS Pathways plc (NASDAQ:CMPS) PT at $47.40

COMPASS Pathways plc (NASDAQ:CMPS) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $47.40.

A number of analysts recently commented on CMPS shares. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, August 23rd. Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $23.00 price objective on shares of COMPASS Pathways in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th.

Institutional Trading of COMPASS Pathways

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quest Partners LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter worth about $33,000. Blue Trust Inc. purchased a new stake in shares of COMPASS Pathways during the second quarter worth about $81,000. Kennedy Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the first quarter worth about $139,000. Tidal Investments LLC grew its position in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after purchasing an additional 5,795 shares in the last quarter. Finally, Fore Capital LLC purchased a new stake in shares of COMPASS Pathways during the second quarter worth about $181,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Up 6.9 %

Shares of NASDAQ:CMPS opened at $7.25 on Wednesday. The company has a market cap of $495.83 million, a P/E ratio of -3.06 and a beta of 2.27. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03. COMPASS Pathways has a 1 year low of $5.01 and a 1 year high of $12.75. The stock’s fifty day moving average price is $7.15 and its 200-day moving average price is $7.94.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same quarter in the prior year, the firm posted ($0.62) earnings per share. Sell-side analysts expect that COMPASS Pathways will post -2.35 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.